<HashMap><database>biostudies-literature</database><scores/><additional><submitter>Ma Y</submitter><funding>BLRD VA</funding><funding>NIA NIH HHS</funding><funding>NIDDK NIH HHS</funding><funding>NIAAA NIH HHS</funding><funding>NCI NIH HHS</funding><funding>National Institutes of Health</funding><funding>U.S. Department of Veterans Affairs</funding><pagination>20989-20997</pagination><full_dataset_link>https://www.ebi.ac.uk/biostudies/studies/S-EPMC5743073</full_dataset_link><repository>biostudies-literature</repository><omics_type>Unknown</omics_type><volume>292(51)</volume><pubmed_abstract>Dineolignans manassantin A and B from the plant &lt;i>Saururus cernuus&lt;/i> are used in traditional medicine to manage a wide range of ailments such as edema, jaundice, and gonorrhea. Cell-based studies have identified several molecular target candidates of manassantin including NF-κB, MAPK, STAT3, and hypoxia-inducible factor 1α (HIF-1α). It is unclear whether or how these structurally diverse proteins or pathways mediate any of the medical benefits of manassantin &lt;i>in vivo&lt;/i> Moreover, it has recently been reported that manassantin causes developmental arrest in zebrafish by inhibiting the mitochondrial complex I, but it is unknown whether manassantin inhibits mitochondrial respiration in intact mammalian cells and live animals. Here, we present direct evidence that manassantin potently an</pubmed_abstract><journal>The Journal of biological chemistry</journal><pubmed_title>The lignan manassantin is a potent and specific inhibitor of mitochondrial complex I and bioenergetic activity in mammals.</pubmed_title><pmcid>PMC5743073</pmcid><funding_grant_id>DK 105961</funding_grant_id><funding_grant_id>DK AA 20758</funding_grant_id><funding_grant_id>R01 DK105961</funding_grant_id><funding_grant_id>2IO1BX001355-01A2</funding_grant_id><funding_grant_id>I01 BX001355</funding_grant_id><funding_grant_id>R21 AG054975</funding_grant_id><funding_grant_id>P30 CA016059</funding_grant_id><funding_grant_id>R01 AA020758</funding_grant_id><pubmed_authors>Hawkridge AM</pubmed_authors><pubmed_authors>Lesnefsky EJ</pubmed_authors><pubmed_authors>Fang X</pubmed_authors><pubmed_authors>Chen Q</pubmed_authors><pubmed_authors>Ma Y</pubmed_authors><pubmed_authors>Mohsin AA</pubmed_authors><pubmed_authors>Wang W</pubmed_authors><pubmed_authors>Oh U</pubmed_authors><pubmed_authors>Sanyal A</pubmed_authors><pubmed_authors>Min HK</pubmed_authors></additional><is_claimable>false</is_claimable><name>The lignan manassantin is a potent and specific inhibitor of mitochondrial complex I and bioenergetic activity in mammals.</name><description>Dineolignans manassantin A and B from the plant &lt;i>Saururus cernuus&lt;/i> are used in traditional medicine to manage a wide range of ailments such as edema, jaundice, and gonorrhea. Cell-based studies have identified several molecular target candidates of manassantin including NF-κB, MAPK, STAT3, and hypoxia-inducible factor 1α (HIF-1α). It is unclear whether or how these structurally diverse proteins or pathways mediate any of the medical benefits of manassantin &lt;i>in vivo&lt;/i> Moreover, it has recently been reported that manassantin causes developmental arrest in zebrafish by inhibiting the mitochondrial complex I, but it is unknown whether manassantin inhibits mitochondrial respiration in intact mammalian cells and live animals. Here, we present direct evidence that manassantin potently an</description><dates><release>2017-01-01T00:00:00Z</release><publication>2017 Dec</publication><modification>2025-04-19T01:47:01.759Z</modification><creation>2019-03-27T00:12:40Z</creation></dates><accession>S-EPMC5743073</accession><cross_references><pubmed>29046352</pubmed><doi>10.1074/jbc.m117.812925</doi><doi>10.1074/jbc.M117.812925</doi></cross_references></HashMap>